Replies to post #6935 on Cel Sci Corporation (CVM)

[Foxwoods Man]

Good article and it give a timeline for the study completion:

CEL-SCI should learn if Multikine achieved the primarily goal of 10% improvement in overall survival over existing standard of care sometime in 2017. A final Phase II study approximated a 33% increase in overall survival for patients who had been administered Multikine over other patients who just received the existing standard of care at 3.5 years after surgery. For Phase III the FDA indicated it would be satisfied with a 10% improvement. Upon the death of the 298th of at least 680 measurable patients enrolled survivability can be measured. Only then will CEL-SCI learn if it has succeeded or failed to achieve the Gold Standard of Survivability in the Phase III trial.

...and I live just south of the Artic (a.k.a Boston) and, after 7 or so feet, decided to leave the snow behind for 6 weeks. Best decision ever....and, beers it is in 2018 (I love SD...been there quite a few times)